Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Dosing Is Achilles Heel For Pfizer’s First Candidate
Executive Summary
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.
You may also be interested in...
Pfizer Sees Once Daily Danuglipron In The “Reasonable Future”
The obesity market offers big revenue potential but Pfizer’s oral GLP-1 candidate is currently dosed twice daily.
William Pao On Pfizer’s ‘Aspirational’ Drug Development Goal, Seagen And More
Chief development officer William Pao oversees Pfizer’s clinical pipeline. He joined the company from Roche following a career in academia, and after his first year at Pfizer talked to Scrip about the transition to late-stage drug development.
With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA
Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau.